Publications

Mild and Diazo-Free Synthesis of Trifluoromethyl-Cyclopropanes Using Sulfonium Ylides.Cyr P, Flynn-Robitaille J, Boissarie P, Marinier AOrg. Lett. 2019-04-05;21(7):2265-2268.

Identification of Allosteric Inhibitors against Active Caspase-6.Tubeleviciute-Aydin A, Beautrait A, Lynham J, Sharma G, Gorelik A, Deny LJ, Soya N, Lukacs GL, Nagar B, Marinier A, LeBlanc ACSci Rep 2019-04-02;9(1):5504.

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau GBlood Adv 2019-02-26;3(4):552-563.

Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, Lemieux S, Marinier A, Pabst C, Rivard GÉ, Hébert J, Sauvageau GLeukemia 2018-06-01;32(6):1349-1357.

Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity.Simon L, Lavallée VP, Bordeleau ME, Krosl J, Baccelli I, Boucher G, Lehnertz B, Chagraoui J, MacRae T, Ruel R, Chantigny Y, Lemieux S, Marinier A, Hébert J, Sauvageau GClin. Cancer Res. 2017-11-15;23(22):6969-6981.

A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau GBlood Cancer J 2017-02-17;7(2):e529.

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang JSci Transl Med 2017-01-04;9(371).

High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.Gerby B, Veiga DF, Krosl J, Nourreddine S, Ouellette J, Haman A, Lavoie G, Fares I, Tremblay M, Litalien V, Ottoni E, Kosic M, Geoffrion D, Ryan J, Maddox PS, Chagraoui J, Marinier A, Hébert J, Sauvageau G, Kwok BH, Roux PP, Hoang TJ. Clin. Invest. 2016-12-01;126(12):4569-4584.

Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.Normandin K, Lavallée JF, Futter M, Beautrait A, Duchaine J, Guiral S, Marinier A, Archambault VSci Rep 2016-11-22;5:37581.

Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.Lavallée VP, Krosl J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J, Sauvageau GBlood 2016-06-16;127(24):3054-61.

Page précédente   |   Page suivante

Suivez l'IRIC

Logo UdeM